(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 13.49% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.95%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.03%.
Exact Sciences's revenue in 2024 is $2,499,766,000.On average, 7 Wall Street analysts forecast EXAS's revenue for 2024 to be $514,234,569,734, with the lowest EXAS revenue forecast at $511,572,418,103, and the highest EXAS revenue forecast at $517,036,500,209. On average, 7 Wall Street analysts forecast EXAS's revenue for 2025 to be $584,813,628,172, with the lowest EXAS revenue forecast at $578,103,517,508, and the highest EXAS revenue forecast at $596,659,612,955.
In 2026, EXAS is forecast to generate $653,547,787,393 in revenue, with the lowest revenue forecast at $653,547,787,393 and the highest revenue forecast at $653,547,787,393.